Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1 Completed 24 enrolled AstraZeneca Bristol-Myers Squibb · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.

Timeline

Start: 2010-08
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dapagliflozin	Small molecule	10 mg	Oral

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Summary

Timeline

Drugs

Indications